Latest Licensing Agreements News

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

AdAlta Limited has received a $0.78 million Research and Development Tax Incentive refund for FY2025, using part of it to repay a Radium Capital loan and strengthening its cash position as it nears a key licensing milestone.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

First Graphene has locked in a 12-month exclusive global license to develop and sell graphene-enhanced carbon paste, a breakthrough material already boosting solar cell efficiency and cutting costs.

LaserBond’s 2025 AGM reveals a pivotal CEO transition alongside a strong financial rebound driven by strategic investments and technology licensing deals.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Linius Technologies has secured a 12-month extension with Racing.com and reported ahead-of-schedule progress on its AI-powered proof of concept with a top European soccer league, signaling growth in sports media technology.